Introduction {#Sec1}
============

Brain atrophy assessment is important in clinical and research neuroradiology settings. When evaluating brain atrophy, tissue loss is assumed when the peripheral and central cerebral spinal fluid (CSF) spaces are enlarged in relation to the intracranial volume \[[@CR1]\]. Brain atrophy is an important imaging sign in cerebral small vessel disease (SVD) \[[@CR2]\], which is the most common cause of vascular dementia and causes one-fifth of all strokes worldwide \[[@CR2], [@CR3]\]. Also, brain atrophy predicts conversion to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) \[[@CR4]\].

Brain atrophy can be evaluated by means of quantitative brain volume measurements, or it can be visually scored by means of rating scales such as the global cortical atrophy (GCA) scale \[[@CR5]\] and the medial temporal lobe atrophy (MTA) scale \[[@CR6], [@CR7]\]. Quantitative brain volume measurements are mainly used in research, because of their relative reliability and good sensitivity compared to visual scores. Typically, brain volume is expressed as a percentage of the intracranial volume. This requires both a T~1~-weighted and a T~2~-weighted sequence \[[@CR1]\] in which the T~1~-weighted sequence is used to assess brain volume, while the T~2~-weighted sequence is used for the measurement of intracranial volume \[[@CR1]\]. Currently, no image segmentation method is completely accurate, as brain tissue voxels containing CSF partial volume will bring in errors in volume measurements, even with high-resolution images \[[@CR8], [@CR9]\]. Despite these inaccuracies, volumetric magnetic resonance imaging (MRI) can predict conversion to AD in accordance with the GCA and the MTA \[[@CR10], [@CR11]\]. So far, no diagnostic threshold for computerized brain atrophy evaluation has been established. Moreover, the currently available segmentation techniques are not easily implemented in daily clinical care. Therefore, visual rating scales remain the gold standard in the clinical setting. Unfortunately, the GCA \[[@CR5]\] and the MTA scales \[[@CR6], [@CR7]\] suffer from subjectivity. Inter-observer agreement for the GCA scale varies from poor to substantial (kappas of 0.34 and 0.7) \[[@CR5], [@CR8]\], whereas the MTA scale seems more robust with inter-observer agreements between 0.82 and 0.9 \[[@CR12]\].

Recently, Qin \[[@CR9]\] suggested a simple approach to map and measure baseline CSF volume fraction \[[@CR9]\] as a surrogate for brain parenchymal volume, which could thus be used to evaluate brain atrophy. The approach is based on the long transverse relaxation rate of CSF (T~2,CSF~) \[[@CR13]\] as compared to other tissue types \[[@CR14]\]. It allows for measuring the CSF volume and T~2,CSF~ simultaneously. Apart from its potential as a surrogate for brain atrophy measurements, the latter measurement (T~2,CSF~) may reflect the CSF contents.

The main purpose of this study was to investigate the ability of this new, fast sequence (scan time of 1:11 min) to act as a surrogate for brain atrophy. A second purpose was to measure the T~2~ of the CSF and to investigate how it relates to the GCA and MTA scales.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

This study contains data from two ongoing studies in our institution, which were both approved by the medical ethical review board of the University Medical Center Utrecht (Utrecht, The Netherlands). The experiments were performed according to the guidelines and regulations of the WMO ('Wet Medisch wetenschappelijk Onderzoek'). Twenty-two subjects were included as control subjects in a study of large vessel disease (NL39070.041.11) and six subjects were included in the 'Parelsnoer' study, which investigates cognitive disorders. The inclusion criteria for the control subjects in the large vessel disease study were: (1) no history of cerebrovascular disease or other brain diseases, and (2) no structural lesions seen on MR imaging (conventional MRI and MR angiography). Inclusion criteria for the subjects included in the 'Parelsnoer' study were: (1) patients referred to a memory clinic for the evaluation of cognitive problems, and with a clinical dementia rating scale of 0, 0.5 and 1 \[[@CR15]\], and a Mini Mental State Examination (MMSE) of 20 or higher \[[@CR16]\]. Exclusion criteria for the subjects included in the 'Parelsnoer' study were: (1) Normal Pressure Hydrocephalus, (2) Morbus Huntington, (3) history of cerebrovascular disease, (4) history of schizophrenia, bipolar disorder, psychotic symptoms or major depressive disorder, (5) alcohol abuse, and (6) history of other brain diseases (brain tumour, epilepsy, encephalitis). All subjects signed informed consent. Data of subjects of both studies were combined to obtain one pool of subjects with larger age and brain atrophy variation. The mean (standard deviation, sd) age of the subjects was 65 (12) years, range: 30--80 years. Of the 28 subjects, 19 subjects were male \[mean (sd) age: 67 (11) years, range: 30--80 years\] and nine were female \[mean (sd) age: 63 (14) years, range: 30--79 years\].

MR imaging {#Sec4}
----------

MR imaging was performed at 3 Tesla (Achieva, Philips, Best, The Netherlands). A 3D T~1~-weighted sequence (matrix 228x227, FOV 250 × 250 × 179 mm^3^, TR 7.2 ms, TE 3.5 ms, scan time 2:52 min) and CSF MRI (voxel 3 × 3 × 6 mm^3^, TR 7917 ms, scan time 1:11 min) \[[@CR9]\] were performed. In the subjects who were part of the large vessel disease study, a higher resolution CSF MRI sequence (1 × 1 × 4 mm^3^) was performed as well. The CSF MRI sequence exploits the long T~2~ properties of the CSF to obtain a pure CSF map. By using a T~2~-preparation scheme, the T~2~ decay within each voxel can be fitted, from which the T~2~ can be estimated. Next, the fitted signal at TE = 0 \["S(0)"\] is compared to the signal of pure ventricular CSF voxels, and based on this, the amount of CSF within each voxel is estimated. This yields accurate measurements of the CSF volume fraction (CSF~VF~) within the voxel \[[@CR9]\]. From the obtained data, CSF volume maps and R~2,CSF~ (= the inverse of the T~2,CSF~) maps are obtained (Fig. [1](#Fig1){ref-type="fig"}). More detailed information regarding the CSF sequence can be found in the online [supplementary material](#Sec14){ref-type="sec"}. In Fig. [2](#Fig2){ref-type="fig"}, the sequence chart of the CSF MRI sequence is shown. The R~2,CSF~ maps were used to calculate the T~2~ of the CSF. The CSF volume maps were used to estimate the CSF volume (V~CSF~), which was expressed as a percentage of intracranial volume. Based on the first echo (eTE = 0 ms) of the CSF MRI sequence, which includes both parenchymal and CSF signal, the intracranial volume (ICV) was measured. Region-of-interest (ROI) analyses (Fig. [1c](#Fig1){ref-type="fig"}) were performed to obtain peripheral subarachnoidal and ventricular CSF volumes and mean T~2,CSF~ values within these regions.Fig. 1***A*** **)** CSF M~0~ map; the signal in each voxel is scaled to pure ventricular voxels to estimate the partial volume effect from which the CSF volume can be calculated. ***B*** **)** R~2~ (= the inverse of the T~2~) CSF map. ***C*** **)** Regions of interest used to retrieve the peripheral subarachnoidal (*red*) and ventricular T~2,\ CSF~ valuesFig. 2CSF MRI sequence chart, the sequence is built of three parts. (1) Part 1, a nonselective (NS) saturation pulse followed by a time delay. (2) Part two, a NS MLEV T~2~-preparation, based on a τ~CPMG~ of 70 ms and 0, 4, 8, and 16 refocusing pulses. From these, effective TEs of 0, 280, 560, and 1120 ms are created. (3) In between parts 2 and 3, an optional inversion pulse can be applied which can compensate for slice-timing differences in multi-slice readout. (4) Part three, a multi-slice single-shot echo planar imaging (EPI) readout

Data analysis {#Sec5}
-------------

From the low and high resolution CSF MRI data, the following CSF volumes were obtained: V~CSF~ (total) = total CSF volume expressed as a percentage of ICV, V~CSF~ (PS) = peripheral subarachnoidal CSF volume expressed as a percentage of ICV, V~CSF~ (V) = ventricular CSF volume expressed as a percentage of ICV. The following T~2,CSF~ values were obtained: T~2,CSF~ (total) = the mean T~2,CSF~ value in the total CSF, T~2,CSF~ (PS) = mean T~2,CSF~ value measured in the peripheral subarachnoidal CSF, T~2,CSF~ (V) = mean T~2,CSF~ value measured in the ventricles. Qualitative imaging scales \[[@CR5]--[@CR7]\] (Table [1](#Tab1){ref-type="table"}) were used to score (blinded) brain atrophy by two readers (J.H., experienced neuroradiologist, 10 years of experience and J.B.D.V., 4 years of experience). The first reader (J.H.) scored the images twice with an interval of one year in between. A detailed description of this is given in the online [supplementary material](#Sec14){ref-type="sec"}. To perform a standard quantitative (computerized) brain atrophy evaluation, data of the 3D T~1~-weighted sequence were processed using FMRIB Software Library (FSL, FMRIB,Oxford, UK). For this, brain tissue voxels of the T~1~-weighted sequence were isolated with the brain extraction tool (BET) \[[@CR17]\]. Subsequently, FAST (FMRIB's Automated Segmentation Tool) was used to obtain grey matter, white matter and CSF maps, and from this, brain parenchymal volumes were calculated.Table 1GCA and MTA scaleGCA scale for global cortical atrophyScore0No cortical atrophy1Mild atrophy: opening of sulci2Moderate atrophy: volume loss of gyri3Severe atrophy: 'knife blade' atrophy'MTA scale for medial temporal lobe atrophyScore0No atrophy1Only widening of choroid fissure2Also widening of temporal horn of lateral ventricle3Moderate loss of hippocampal volume (height)4Severe volume loss of hippocampus

Statistical analysis {#Sec6}
--------------------

Statistical analysis was carried out with R version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) \[[@CR18]\] and IBM SPSS statistics version 19.0.1 (SPSS Inc., Chicago, Illinois). As an earlier study demonstrated that a quarter of brain volume variation is explained by gender \[[@CR19]\], we first performed a Mann-Whitney U test to compare the distribution of the GCA and MTA scores between male and female subjects. Similarly, the ICV of males versus females were compared, and the relative total CSF volumes of males versus females were compared.

Cohen's kappa statistics were used to evaluate the inter-rater and intra-rater agreement for the GCA and MTA scores. Linear regression analyses were used to correlate relative total, peripheral subarachnoidal and ventricular CSF volumes (obtained from the low resolution CSF MRI data) to the GCA and MTA scores. Similarly, linear regression analyses were used to correlate total, peripheral subarachnoidal, and ventricular T~2,CSF~ values to the GCA and MTA scores.

Linear regression analysis was performed to compare the brain parenchymal volumes measured with the CSF MRI sequence to the brain parenchymal volumes measured with FMRIB Software (based on a T~1~-weighted image).

Two analyses were performed to evaluate the influence of partial volume effects on the obtained values. First, the results of the low resolution CSF MRI sequence were compared against the results of the high resolution CSF MRI sequence. For this, the values obtained for global cortical atrophy and the T~2~ measured within the peripheral subarachnoidal space were compared using a paired samples *t*-test. Second, the ventricular ROI's were eroded, after which the mean T~2,CSF~ values obtained from within these smaller ROIs were compared against the mean T~2,CSF~ values obtained within the actual ventricular ROIs. To evaluate the difference between the results of both these ROIs, a paired samples *t*-test was used.

In our study protocol no test-retest study was included, as the earlier reproducibility test performed by Qin \[[@CR9]\] demonstrated an excellent robustness of the CSF MRI sequence for measuring the CSF volumes and a good robustness for measuring the T~2,CSF~ (0.7 \< R^2^ \< 0.85). Though, as an attempt to evaluate the agreement of the CSF MRI sequence within our study, we compared the results of the low resolution CSF MRI sequence against the results of the high resolution CSF MRI sequence. This was done by means of a Bland-Altman scatter plot analysis demonstrating the mean difference and limits of agreement.

Results {#Sec7}
=======

Table [2](#Tab2){ref-type="table"} shows the mean, standard deviation (sd) and range of GCA and MTA scores, ICV and relative total CSF volume. No significant differences in age, GCA and MTA scores, and relative total CSF volume (18.1 % versus 16.0 %) between males and females were found. ICV was significantly different in the males compared to the females (1524 cm^3^ versus 1361 cm^3^, *p* \< 0.01). The inter-rater agreements for the GCA and MTA scores were moderate; 0.36 and 0.52 (*p* \< 0.01 and \< 0.001). The intra-rater agreements for the GCA and MTA scores were moderate to fair; 0.58 and 0.62 (*p* \< 0.001).Table 2Subject characteristicsAllMaleFemaleN28199Age Mean (sd)65 (12)67 (11)63 (14) Range30 -- 8030 -- 8030 -- 79GCA Mean (sd)1 (1)1 (1)1 (1) Range0 -- 20 -- 20 -- 2MTA Mean (sd)1 (1)1 (1)1 (1) Range0 -- 40 -- 40 -- 2ICV (cm^3^) Mean (sd)1471 (146)1524 (115)1361 (148) Range1081 -- 16551306 -- 16551081 -- 1552V~CSF~ (total) (%) Mean (sd)17.4 (4.3)18.1 (4.0)16.0 (4.7) Range11.1 -- 26.112.1 -- 25.511.1 -- 26.1GCA, global cortical atrophy; MTA, medial temporal lobe atrophy; ICV, intracranial volume; V~CSF~ (total), relative total cerebrospinal fluid (CSF) volume (= total CSF volume expressed as a percentage of intracranial volume); sd, standard deviationIntracranial volume was significantly different between males and females (*p* \< 0.01). No significant differences in age, GCA and MTA score were found

Brain atrophy and whole brain CSF measurements {#Sec8}
----------------------------------------------

Table [3](#Tab3){ref-type="table"} shows the number of subjects for each score on the qualitative imaging scales (GCA and MTA scale) and their corresponding mean (± sd) relative total CSF volumes (total CSF volume expressed as a percentage of ICV), and mean (± sd) total T~2,CSF~. The correlation between the GCA and the MTA score and the relative total CSF volumes was significant (R = +0.83 and +0.72, *p* \< 0.001). The correlation between the GCA and the MTA score and total T~2,CSF~ was significant (R = +0.72 and +0.60, *p* \< 0.001 and \< 0.01).Table 3Brain atrophy and whole brain CSF measurementsNV~CSF~ (total)\
(%)T~2,CSF~ (total)\
(ms)GCA**0**512.5 ± 1.11182 ± 60**1**1716.7 ± 2.61339 ± 111**2**623.5 ± 2.51528 ± 138**3**------CorrelationR = +0.83 (*p* \< 0.001)R = +0.72 (*p* \< 0.001)MTA**0**1115.0 ± 3.21255 ± 109**1**1116.7 ± 2.71360 ± 130**2**321.6 ± 4.31512 ± 211**3**225.0 ± 0.71506 ± 71**4**123.71522CorrelationR = +0.72 (*p* \< 0.001)R = +0.60 (*p* \< 0.01)GCA, global cortical atrophy; MTA, medial temporal lobe atrophy; V~CSF~ (total), relative total cerebrospinal fluid (CSF) (= total CSF volume expressed as a percentage of intracranial volume); T~2,CSF~ (total), the mean T~2~ value of the total cerebrospinal fluidFor each category of GCA and MTA score, the CSF volume and the T~2,CSF~ are shown

Brain atrophy and regional CSF measurements {#Sec9}
-------------------------------------------

Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} in the online [supplementary material](#Sec14){ref-type="sec"} show the correlation between the GCA and the MTA scores with relative peripheral subarachnoidal and ventricular CSF volumes and T~2,CSF~. Table [4](#Tab4){ref-type="table"} shows the number of subjects for each score on the qualitative imaging scales (GCA and MTA scale) and their corresponding mean (± sd) relative peripheral subarachnoidal and relative ventricular CSF volumes. The correlations between the GCA scores and the relative peripheral subarachnoidal and the relative ventricular CSF volumes were significant (R = +0.78 and +0.78, *p* \< 0.001). The correlations between the MTA scores and the relative peripheral subarachnoidal and relative ventricular CSF volumes were significant (R^2^ = +0.62 and +0.86, *p* \< 0.001). The correlation between the GCA scores and the peripheral subarachnoidal and ventricular T~2,CSF~ values were significant (R = +0.70 and +0.49, p \< 0.001 and \< 0.01). The correlation between the MTA scores and the peripheral subarachnoidal and ventricular T~2,CSF~ values were significant (R = +0.57 and +0.41, *p* \< 0.01 and \< 0.05) (Table [5](#Tab5){ref-type="table"}).Table 4Brain atrophy and regional CSF volumesNV~CSF~ (PS)\
(%)V~CSF~ (V)\
(%)GCA**0**510.1 ± 0.91.0 ± 0.3**1**1713.2 ± 2.01.7 ± 0.7**2**617.5 ± 2.33.7 ± 0.9**3**------CorrelationR = +0.78 (*p* \< 0.001)R = +0.78 (*p* \< 0.001)MTA**0**1112.1 ± 2.61.2 ± 0.4**1**1113.0 ± 2.01.9 ± 0.7**2**316.2 ± 3.73.3 ± 0.2**3**219.1 ± 0.13.3 ± 0.7**4**116.55.4CorrelationR = +0.62 (*p* \< 0.001)R = +0.86 (*p* \< 0.001)GCA, global cortical atrophy; MTA, medial temporal lobe atrophy; V~CSF~ (PS), relative peripheral subarachnoidal cerebrospinal fluid (CSF) volume (= peripheral subarachnoidal CSF volume expressed as a percentage of intracranial volume); V~CSF~ (V), relative ventricular CSF volume ( = ventricular CSF volume expressed as a percentage of intracranial volume).For each category of GCA and MTA score, the V~CSF~ (PS) and the V~CSF~ (V) are shownTable 5Brain atrophy and regional CSF T~2~ valuesNT~2,CSF~ (PS)\
(ms)T~2,CSF~ (V)\
(ms)GCA**0**51150 ± 701774 ± 217**1**171305 ± 1171992 ± 111**2**61493 ± 1422000 ± 86**3**------CorrelationR = +0.70 (*p* \< 0.01)R = +0.49 (*p* \< 0.01)MTA**0**111225 ± 1121834 ± 176**1**111324 ± 1391954 ± 98**2**31479 ± 2181965 ± 96**3**21478 ± 711930 ± 10**4**114662125CorrelationR = +0.57 (*p* \< 0.01)R = +0.41 (*p* \< 0.05)GCA, global cortical atrophy; MTA, medial temporal lobe atrophy; T~2,CSF~ (PS), the mean T~2~ value of the peripheral subarachnoidal cerebrospinal fluid; T~2,CSF~ (V)~,~ the mean T~2~ value of the ventricular cerebrospinal fluidFor each category of GCA and MTA score, the T~2,CSF~ (PS) and the T~2,CSF~ (V) are shown

CSF MRI sequence versus standard computerized brain atrophy evaluation {#Sec10}
----------------------------------------------------------------------

In one subject, the computerized segmentation failed during brain extraction and this subject was thus excluded from the analysis. The mean (sd) brain volume measured using the CSF MRI sequence was 1212 (122) ml. The mean (sd) brain volume derived from the 3D-T~1w~ MRI sequence was 1008 (106) ml. The brain parenchymal volumes (BPV), measured by means of the CSF MRI sequence and the 3D-T~1w~ MRI sequence showed a very strong correlation: R = 0.85, BPV~CSF-MRI~ = 232 (± 123) + 0.97 (± 0.12) · BPV~3D-T1wMRI~, *p* \< 0.01.

Partial volume effects {#Sec11}
----------------------

The peripheral subarachnoidal CSF volumes, measured by means of a low (12.5 ± 2.3 %) and a high resolution (11.8 ± 4.7 %) CSF MRI sequence, were not significantly different (*p* = 0.38). The T~2~ of the CSF within the peripheral subarachnoidal space as measured by means of a low (1275 ± 129 ms) and high resolution (1420 ± 183 ms) CSF MRI sequence were significantly different (*p* \< 0.001). The mean (sd) T~2,CSF~ in the ventricular mask was 1912 (145) ms. The mean (sd) T~2,CSF~ in the eroded (smaller) ventricular ROI was 2060 (153) ms. These were significantly different (*p* \< 0.001).

Agreement analysis {#Sec12}
------------------

In Fig. [3](#Fig3){ref-type="fig"}, a Bland-Altman scatter plot demonstrates the agreement between the low and high resolution CSF MRI sequence for both the total CSF volume and the T~2,CSF~. The mean difference of the total CSF volume was 30.8 (± 70.7) ml. This difference was not significant (*p* = 0.054). The mean difference of the T~2,CSF~ was -161.4 (± 132) ms (*p* \< 0.001).Fig. 3Bland-Altman plot demonstrating the agreement between the low and high resolution CSF MRI sequence performed within the same session. The coefficient of repeatability for the relative CSF volumes (figure on the left, CSF volumes expressed as a percentage of intracranial volume), was 14. The coefficient of repeatability for the T~2~ within the total CSF was 9.5

Discussion {#Sec13}
==========

We demonstrated that a fast CSF MRI sequence with an imaging time of 1:11 minutes and fast post-processing without user interaction can be used to obtain the intracranial volume, the CSF volume and the T~2~ relaxation time constant of the CSF. The obtained volume measurements correlated well with the qualitative atrophy scales, which show that the CSF MRI sequence can be used to evaluate brain atrophy. We found a high correlation between the T~2~ of the CSF and the qualitative atrophy scales. The T~2~ of the CSF could thus be a marker for neurodegenerative diseases.

Over the last few years, an increasing number of research groups have started to use image segmentation tools, which are used to measure the brain parenchymal volume, instead of qualitative image atrophy scores to evaluate brain atrophy. In this paper, the percentage of CSF was used as a surrogate for brain parenchymal volume. The method that we used to obtain the CSF volume exploits the long T~2~ of the CSF to isolate its signal. By fitting T~2~ decay within each voxel, and comparing the fitted signal at TE = 0 \["S(0)"\] to the signal of pure ventricular CSF voxels, the amount of CSF within each voxel is estimated. This yields accurate measurements of the CSF volume fraction within the voxel \[[@CR9]\], from which regional CSF volumes can be obtained. We limited ROI analyses to the peripheral subarachnoidal and the ventricular space. However, this could be extended to obtain measurements of, for instance, frontal, parietal or temporal CSF volume, and thus provide an assessment of regional atrophy. Regional atrophy assessment could potentially enable classification of dementia diseases based on their atrophy patterns \[[@CR20]\]. For instance, AD and frontotemporal lobe degeneration are both associated with medial temporal lobe atrophy \[[@CR21]--[@CR24]\]. The combined presence of either temporal and posterior, or temporal and frontal atrophy may help to distinguish between both \[[@CR25]--[@CR27]\]. Additionally, regional measurements could be helpful when differentiating ventriculomegaly or hydrocephalus from brain atrophy. Enlarged ventricular CSF volume without an increase in peripheral subarachnoidal CSF volume could guide the assessor towards ventriculomegaly or hydrocephalus instead of brain atrophy. It should be noted that the CSF MRI sequence cannot differentiate between gray or white matter loss, and as such, can only supplement conventional MRI sequences but not replace them.

In this paper, we compared the results of the brain parenchymal volume measurements obtained from our CSF MRI sequence to the results of a more standard computerized quantitative brain atrophy evaluation. We demonstrated a strong correlation between both brain parenchymal volume measurements. The linear analysis showed that our CSF MRI sequence estimates the ICV as systematically larger than the T~1~-based segmentation method by about 230 ml. This is probably due to a slight difference, in between both methods, in the exact (subvoxel) localization of the border between CSF and tissue. As well, small amounts of variation may be explained by partial volume effects in either the 3D-T~1w~ sequence, caused by the inclusion of brain tissue in CSF voxels, or by partial volume effects in our CSF MRI sequence, which are discussed below. More recent segmentation software may perform even better, but the scope of our comparison was to compare to standard available segmentation software.

An earlier study demonstrated that over half of the variation in brain volume can be explained by ICV and a quarter of the variation in brain volume can be explained by gender \[[@CR19]\]. This was confirmed in our study, as we demonstrated a significantly different ICV in male compared to female subjects. The strength of the approach presented in this paper is that it accounts for this variation by expressing CSF volumes as a ratio to the ICV.

We found an increase in the T~2,CSF~ with increased visual ratings of global cortical and medial temporal lobe atrophy. Qin suggested that the regional variation in T~2,CSF~ is likely explained by variation in the composition of the CSF \[[@CR9]\]. The CSF composition in patients can be different due to both differences in O~2~ partial pressure and differences in CSF protein content. Zaharchuk found a profound effect of oxygen partial pressure on the longitudinal relaxation rate (T~1~) of the CSF \[[@CR28]\]. Even more so, they showed that inhalation of 100 % oxygen changed the T~1~ of CSF, an effect which was most pronounced in the cortical sulci \[[@CR29]\]. This matches with our findings, which show that the T~2~ of the peripheral subarachnoidal CSF has a stronger relationship with the GCA and MTA scale than the T~2~ of the ventricular CSF. We hypothesize that subjects with more brain atrophy have a lower oxygen content of CSF. Small vessel disease could lead to decreased brain perfusion and thus decreased oxygen diffusion from the blood vessels towards the CSF. A decrease in oxygen content would lead to a longer T~2,~ which would correspond to our observations. Unfortunately, we were not able to measure the partial oxygen pressure of CSF in our subjects and thus to investigate this phenomenon. Further research with dedicated measurements of the partial oxygen pressure in the CSF are needed to investigate this. So far, the partial oxygen pressure of the CSF within this patient population has not been investigated, as the measurements are rather difficult to perform. Besides oxygen pressure, changes in the protein content of the CSF related to pathology should be investigated as a potential explanation for the regional variation in T~2~ of the CSF. Moreover, though Qin \[[@CR9]\] suggested variation in composition of the CSF as the most likely source for variation in T~2~ of the CSF, it may still be possible that the T~2~ mapping sequence yields systematic errors in the estimated T~2~. These might be related to partial volume effects and imperfections in the excitation and refocusing pulses (heterogeneity in the transmit RF field, B1). Thus, the reproducibility of the method and its robustness against B1 variation (due to the use of an MLEV T2 preparation scheme) should be established in future studies before firm conclusions on the origin of regional T~2~ variation can be drawn.

In this paper, an MLEV scheme was selected based on the initial work of Qin \[[@CR9]\]. The advantage of the pre-pulse approach is that it can match resolution and coverage to other functional scans such ASL and functional MRI. This increases the abilities to perform partial volume corrections within these modalities, which is especially important in populations with varying degrees of atrophy.

Although the CSF MRI sequence seems promising, there are some limitations. One of them is partial volume effects, which could have potentially influenced our results and the found correlations. However, several observations demonstrate that the partial volume effects had no major influence on the results. First, the ventricles should be more or less free of partial volume effects, and we demonstrated that the correlations with the GCA and MTA scores hold true even when only the ventricular CSF volume or T~2,CSF~ were evaluated. In addition, eroding the ventricular masks to smaller ROIs only had a minor influence on the T~2,CSF~ values. Second, we investigated the influence of partial volume effects by comparing the results obtained with a low resolution (3 × 3 × 6 mm^3^) CSF MRI sequence to the results obtained with a high resolution CSF MRI sequence (1 × 1 × 4mm^3^) and found no significant difference between the peripheral subarachnoidal CSF volumes. However, the difference in between the T~2,CSF~, measured with both the low and high resolution CSF MRI sequence in the peripheral subarachnoidal space, was significant. As explained before, this may indicate that the T~2~ has a higher sensitivity to partial volume effects than the CSF volume measurements.

In conclusion, we demonstrated that a fast CSF MRI sequence has the potential to replace qualitative imaging atrophy scales and supplement conventional segmentation methods. The method is advantageous, as it requires little post-processing time and no user interaction. The T~2,CSF~ should be investigated more thoroughly, as it could be a marker for neurodegenerative diseases.
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